Resolution n°9

LYNX p24: Establishing and Sustaining a Market-based Intervention for Early Infant Diagnosis of HIV at the Point of Care

Taking into account the outcome of the PRC review of 3-4 April 2014 and noting the issues raised for further clarification, the Executive Board of UNITAID, subject to the availability of funds, authorizes the Executive Director to commit up to USD 3 704 500 for the project LYNX p24: Establishing and Sustaining a Market-based Intervention for Early Infant Diagnosis of HIV at the Point of Care.

Description: Early market entry support for a new point-of-care early infant diagnosis HIV test ("LYNX p24")

Lead organization(s): Northwestern Global Health Foundation

Consortium members: n/a

Project duration: 3 years

Conditions for UNITAID funding support:

Funding is conditional upon:

- The development of a Project Plan to the satisfaction of the Secretariat, having regard to the issues raised by the PRC during its review. The Project Plan shall include provision for an independent technical verification of quality, together with the performance and operational characteristics of LYNX p24, to be conducted by an internationally recognized agency. The parameters for the verification must be agreed in advance with UNITAID.
- Down-sizing the number of countries, to include a selection of African Tier 1 countries only.
- The satisfactory outcome of the Secretariat’s due diligence and fiduciary assessment, which shall include a freedom to operate analysis of IP rights and a review of the proposed commercialization strategy.
- Review of the budget to ensure that all proposed costs are appropriate and reasonable (including with respect to any third-party recipients), to the satisfaction of the Secretariat.
- Signature of a legal agreement between Northwestern Global Health Foundation and UNITAID, reflecting performance based funding to ensure value for money and principles acceptable to UNITAID on access and IP.

Philippe Douste-Blazy
Chair of the UNITAID Executive Board